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Abstract

Introduction

The intervertebral disc is an important mechanical
structure that allows range of motion of the spinal column.
Degeneration of the intervertebral disc – incited by aging,
traumatic insult, genetic predisposition, or other factors
– is often defined by functional and structural changes
in the tissue, including excessive breakdown of the
extracellular matrix, increased disc cell senescence and
death, as well as compromised biomechanical function
of the tissue. Intervertebral disc degeneration is strongly
correlated with low back pain, which is a highly prevalent
and costly condition, significantly contributing to loss in
productivity and health care costs. Disc degeneration is
a chronic, progressive condition, and current therapies
are limited and often focused on symptomatic pain relief
rather than curtailing the progression of the disease.
Inflammatory processes exacerbated by cytokines tumour
necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) are
believed to be key mediators of disc degeneration and low
back pain. In this review, we describe the contributions of
TNF-α and IL-1β to changes seen during disc degeneration
at both cellular and tissue level, as well as new evidence
suggesting a link between infection of the spine and low
back pain, and the emerging therapeutic modalities aimed
at combating these processes.

The intervertebral disc (IVD) comprises an outer
circumferential annulus fibrosus (AF) and an inner cellsparse, matrix-rich nucleus pulposus (NP), bordered
superiorly and inferiorly by two cartilaginous endplates.
The AF is a lamellar fibrocartilaginous structure rich in
collagen I, derived from embryonic sclerotome, and is
responsible for withstanding large hoop stress from the
pressurised NP, and tensile and torsional stresses from
motion of adjacent vertebrae (Guterl et al., 2013). The NP
encompasses a physiologically hypoxic and hyperosmotic
niche; cells residing within the NP are derived from the
embryonic notochord (Risbud et al., 2010; Risbud and
Shapiro, 2011; Johnson et al., 2014; Choi et al., 2015).
NP cells are phenotypically defined in part by the distinct
ratio of synthesised aggrecan and collagen II (Mwale et
al., 2004; Risbud et al., 2015). The hydrated, aggrecan-rich
extracellular matrix (ECM) resists large compressive loads
from the trunk, allowing us to remain upright (Vergroesen
et al., 2015). Degeneration of the NP, AF and IVD as
a structure is often defined by functional and structural
changes in the tissue, including excessive breakdown
of ECM by proteases and increased cell senescence and
death (Roughley, 2004; Adams and Roughley, 2006). IVD
degeneration is strongly correlated with low back pain
(LBP) (Chou et al., 2011; Livshits et al., 2011), which is
a highly prevalent, costly, and crippling condition across
the globe (Katz, 2006; Hoy et al., 2012). Inflammatory
processes, exacerbated by cytokines tumour necrosis
factor-α (TNF-α) and interleukin-1β (IL-1β) are believed to
be key events during disc degeneration and associated LBP
(Risbud and Shapiro, 2014). In this review, we describe the
specific contributions of TNF-α and IL-1β to cellular and
tissue level changes seen during disc degeneration, discuss
new evidence suggesting a link between infection of the
spine and LBP, and the emerging therapeutic modalities
aimed at combating these processes. Specifically, the
effects of cytokines on breakdown of disc ECM and
potential activation of Toll-like receptors, the immune
response, disc cell homeostasis, and resolution of disc
herniation are discussed, as well as potential triggering
mechanisms for this cytokine activity.

Keywords: Intervertebral disc, nucleus pulposus,
cytokines, extracellular matrix, tumour necrosis factor,
interleukin-1, Toll-like receptor.
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Initiating events that may contribute to elevated
cytokine production by disc cells and spinal tissues
It has been well established that inflammatory changes in
the disc contribute to degeneration, and that trauma and
genetic predisposition may contribute to some aspects of
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this cascade. However, the question remains of the initiating
event(s) that promotes production of these cytokines by
NP and AF cells, especially in the absence of acute trauma
or herniation. One possible initiator is chronic overload
of the disc, which has been shown to cause degenerative
changes in several models (Adams et al., 2000). Discs from
rats subjected to in vivo dynamic compression overloading
over 8 weeks showed increased matrix metalloproteinase
(MMP)-associated aggrecan degradation products in both
the AF and NP compared to sham discs (Iatridis et al.,
2011). Some evidence exists, correlating bacterial infection
with degenerative disc disease and LBP. In one study,
53 % of surgical microdiscectomy samples from patients
with sciatica were positive for bacterial cultures (Stirling
et al., 2001). In another recent study, herniated nuclear
tissue removed during surgery was positive for microbial
cultures in 46 % of patients, and significantly correlated
with Modic changes in adjacent vertebral endplates, which
are highly associated with LBP (Jensen et al., 2008; Albert
et al., 2013a). Additional studies have also shown evidence
of bacterial infection in some painful degenerate discs,
even in the absence of overt clinical infection (Stirling et
al., 2002; Fritzell et al., 2004; Agarwal et al., 2011; Arndt
et al., 2012).
In 2008, Albert et al. (2008a) proposed the hypothesis
that some cases of degenerative disc disease and low back
pain have an infectious cause, supported by a pilot study
investigating the efficacy of antibiotics for the treatment
of patients with persistent LBP and Modic changes that
did not respond to initial conservative therapy (Albert et
al., 2008b). In this pilot study, there was a statistically and
clinically significant improvement in patients receiving
a course of amoxicillin-clavulanate antibiotics. A larger
double-blind randomised clinical trial followed and
similarly reported significant improvement in disability
and pain in patients treated with antibiotics compared to
placebo (Albert et al., 2013b). Importantly, some evidence
suggests that clavulanate has anti-inflammatory and
analgesic properties, which may confound interpretation
of clinical findings by Albert et al. (Casellas et al.,
1998; Hajhashemi and Dehdashti, 2014). In addition,
some investigators have suggested that the presence of
bacteria in disc samples arises from contamination of skin
commensals (e.g. Proprionibacterium acnes) during nonsterile surgical and collection procedures (McLorinan et
al., 2005; Ben-Galim et al., 2006; Carricajo et al., 2007;
Wedderkopp et al., 2009); it may also arise from infected
endplate and bony avulsions (Rajasekaran et al., 2013).
In spite of the controversial nature, subclinical bacterial
infection of endplate/vertebrae and/or discitis as a cause for
disc degeneration and LBP warrants further consideration
and careful investigation.
Bacterial infection of the disc may initiate inflammatory
cascades through activation of components of the innate
immune response. Toll-like receptors (TLRs) are plasmaand endolysosomal-bound pattern recognition receptors,
best characterised as expressed on the surface of cells of
the immune system (De Nardo, 2015). TLRs recognise
pathogen-associated molecular patterns (PAMPs), and
activate inflammatory signalling cascades (Kumar et al.,
2009). Most relevant to bacterial infection are TLR2 and
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TLR4. TLR2 recognises a range of PAMPs including
peptidoglycans expressed in the cell wall of Gram-positive
bacteria (Zähringer et al., 2008), while TLR4 is activated
by lipopolysaccharide (LPS) in the cell wall of Gramnegative bacteria (Poltorak et al., 1998). Activation both
TLR2 and TLR4 signalling results in transcription of many
pro-inflammatory cytokines through the MyD88 pathway
(Kawai et al., 1999).
Interestingly, NP cells also express TLRs with a recent
study identifying expression of TLR1/2/3/4/5/6/9/10 in
isolated human IVD cells. Importantly, expression levels
of TLR2 and TLR4 were raised with increasing grade
of degeneration (Klawitter et al., 2014). Another study
showed that treatment of IVD cells with LPS resulted
in increased expression of TNF-α, IL-1β, and IL-6,
and decreased expression of aggrecan and collagen II.
Furthermore, injection of LPS into discs in vivo induced
degenerative changes (Rajan et al., 2012). Ellman et al.
(2012) demonstrated that inhibition of MyD88 attenuated
the changes in catabolic gene expression incurred by LPS
in vitro as well as in an ex vivo organ culture model. These
studies suggest that not only can innate immunity initiate
degenerative changes in the disc, but it can also perpetuate
inflammatory cascades and promote progressive disease.
The TNF and IL-1 signalling pathways
TNF-α is synthesised by cells as a 26 kDa type II
transmembrane protein termed mTNF. This membranebound form is processed to a 17 kDa soluble form,
sTNF, by the metalloproteinase tumour necrosis factorα-converting enzyme (TACE) also known as ADAM
metallopeptidase domain 17 (ADAM17). The trimeric
forms of both mTNF and sTNF are biologically active,
although monomeric and dimeric forms also exist (Black
et al., 1997). TNF-α interacts with either of two receptors
of the tumour necrosis factor receptor (TNFR) superfamily,
TNFR1 or TNFR2. mTNF can bind either receptor,
while sTNF can bind TNFR1 only. TNFR1 activation by
TNF-α leads to formation of two distinct TNF signalling
complexes: Complex 1 has anti-apoptotic functions,
while Complex II/death inducing signalling complex
(DISC) induces apoptosis after receptor internalisation.
TNFR2, on the other hand, lacks an intracellular death
domain. Therefore, signalling through this complex is
considered anti-apoptotic. Recent evidence, however,
suggests that TNFR2 may induce degradation of TNF
receptor-associated factor 2 (TRAF2), resulting in crosstalk
between the TNFR1 and TNFR2 pathways. Signalling
through Complex I activates the nuclear factor κB (NF-κB)
and mitogen activated protein kinase (MAPK) pathways
(Cabal-Hierro and Lazo, 2012) (See Fig. 1). Relevant to
this review, high levels of TNF-α have been associated with
disc degeneration (discussed in the following sections).
IL-1α and IL-1β, members of the IL-1 family of 11
cytokines, are first synthesised as precursor proteins and
then activated through intracellular proteolytic cleavage by
calpain and caspase-1, respectively. Secreted pro-IL-1β can
also be activated extracellularly by neutrophil proteases.
While pro-IL-1β requires this activation, membrane-bound
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Fig. 1. TNF-α signalling pathway. Membrane-bound TNF (mTNF) is processed by the metalloproteinase TACE/
ADAM-17 to the soluble form (sTNF). sTNF-α or mTNF-α may bind the transmembrane TNFR1 receptor, causing a
conformational change that releases the inhibitory SODD protein. Binding results in the recruitment of several factors
including TRADD, RIP1, TRAF2 and cIAP 1 and 2, resulting in formation of Complex I that signals through either
the NF-κB or MAPK pathways to activate p65 or AP1, respectively. Complex I signalling results in transcription of
inflammatory (chemokines, cytokines) and matrix catabolic genes (MMPs, ADAMTSs) as well as pro-survival genes
(cIAP1 and 2, cFLIP, TRAF1, TRAF2). Alternatively, mTNF-α may activate the TNFR2 receptor to form a similar
complex and downstream signalling cascade. In some instances, TNFR1 bound to sTNF-α may be internalised, initiating
Complex II or DISC formation that leads to cleavage of procaspase 8 and finally cell apoptosis. Abbreviations: TNF-α,
tumour necrosis factor α; TACE, TNF-α converting enzyme; ADAM-17, a disintegrin and metalloproteinase domain
containing protein 17; TNFR1, TNF receptor 1; SODD, silencer of death domains; TNFR2, TNF receptor 2; TRADD,
TNFR1-assoicated death domain protein; RIP1, receptor-interacting protein 1; TRAF2, TNF-receptor-associated
factor 2; cIAP, baculoviral IAP repeat containing; DISC, death-inducing signalling complex; NF-κB, nuclear factor
κB; MAPK, mitogen-activated protein kinase; DD, death domain.

pro-IL-1α can signal through interleukin 1 receptor type
I (IL-1R1) on adjacent cells without proteolytic cleavage.
In addition, the 16 kDa N-terminal propeptide cleavage
product of pro-IL-1α (ppIL-1α) can translocate into the
nucleus and is thought to function as a transcriptional
modulator. Both IL-1α and IL-1β through binding IL-1R1,

can stimulate NF-κB, JNK, and p38 MAPK signalling
pathways, resulting in phosphorylation of various proteins
involved in transcription of inflammatory and catabolic
genes such as IL-6, IL-8, MCP-1, COX-2, IκBα, IL-1α,
IL-1β and MKP-1 (Gabay et al., 2010; Weber et al., 2010).
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TNF and IL-1 are closely associated with
intervertebral disc degeneration
Associations between herniation, disc degeneration, and
the inflammatory response have been well established.
Herniated disc tissue exhibits a large inflammatory cell
response with macrophages being predominant players
and increased TNF-α, IL-1β and many other cytokines
detected at the site of herniation (Grönblad et al., 1994;
Takahashi et al., 1996). A 2012 study of NP samples
from adolescent patients found an increased number of
TNF-α-immunoreactive cells in painful herniated samples
compared to non-painful scoliotic controls (Ohtori et al.,
2012a). Importantly, during disc degeneration TNF-α and
IL-1β are not only produced by leukocytes, but also by IVD
cells themselves (Le Maitre et al., 2005; Le Maitre et al.,
2007b). In addition, TNFR1, TNFR2, TACE, interleukin-1
receptor antagonist (IL-1ra) and IL-1R1 are expressed in
human nucleus pulposus tissue, and expression of TNF-α
and IL-1β increases with age and severity of degeneration
in both humans and animal models (Oda et al., 2004; Le
Maitre et al., 2005; Bachmeier et al., 2007; Le Maitre
et al., 2007b; Wang et al., 2013b). Furthermore, another
study confirmed expression of both TNFR1 and TNFR2
in NP tissue from patients with disc herniation, with levels
of TNFR1 being positively correlated with degree of
pain (Andrade et al., 2011). In addition, IL-1 gene family
polymorphisms, IL-1RN G1812A, IL-1α C889T, and
IL-1β C3954T, are associated with increased risk of LBP
(Solovieva et al., 2004). Importantly, expression of these
cytokines is not merely correlated with degeneration, but
is believed to be causative of disease.
TNF and IL-1 contribute to disc disease through
degradation of ECM
One meaningful characteristic of disc degeneration is
disruption of the ECM. TNF-α and IL-1β have been
shown in many contexts to induce degenerative changes
to the ECM. Induction of catabolic enzymes a disintegrin
and metalloproteinase with thrombospondin motifs
(ADAMTS)-4 and -5, and matrix metalloproteinases
(MMPs) -1, -2, -3, -4, -13 and -14, and concurrent decrease
in expression of anabolic ECM proteins aggrecan and
collagen II is mediated by both IL-1β and TNF-α (Doita
et al., 2001; Shen et al., 2003; Jimbo et al., 2005; Le
Maitre et al., 2005; Séguin et al., 2005; Murata et al.,
2006; Le Maitre et al., 2007a; Bachmeier et al., 2009;
Pockert et al., 2009; Wang et al., 2011; Wang et al.,
2014a). Séguin et al. (2008) showed that TNF-α-induced
increase in MMP2 activity was specifically associated
with upregulation of membrane type MT1-MMP. A
recent study by Ye et al. (2015) showed that unlike in
chondrocytes, NP cell expression of xylosyltransferase-1
(XT-1), a key enzyme in glycosaminoglycan synthesis, is
unaffected by TNF-α and IL-1β treatment, suggesting that
the effects of these cytokines on the ECM homeostasis
are fairly cell-type-specific. Further studies have shown
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that TNF-mediated activation of ADAMTS4 occurs
through ERK1, p38 and NF-κB pathways in NP cells
(Tian et al., 2013). In organ culture models, treatment
with TNF-α resulted in suppression of multiple collagen
types, aggrecan, fibromodulin, increased expression of
MMPs and pain-associated molecule nerve growth factor
(NGF) (Ponnappan et al., 2011), and compromised disc
biomechanics (Walter et al., 2015a). These results contrast
with that of Hoyland et al. (2008), which showed that
TNF-α treatment had little effect on matrix degradation
as assessed by in situ zymography on gelatin, collagen II,
and casein, although changes were seen after treatment
with IL-1β. This differential response may be explained by
differences in concentration, duration of TNF-α treatment,
culture system, and/or species between the studies. Not
surprisingly, the relative importance of each of these
inflammatory mediators is still debated. Nonetheless,
both of these cytokines have been shown under numerous
conditions to control catabolic gene expression in disc
tissues.
TNF-α and IL-1β also suppress expression of
matricellular protein connective tissue growth factor
(CCN2/CTGF), an important regulator of cellular adhesion,
proliferation, migration and ECM synthesis (Tran et al.,
2010; Tran et al., 2014). Tran et al. (2014) demonstrated
that the activity of these cytokines on CCN2 expression
was NF-κB-dependent. In addition, CCN2 successfully
suppressed IL-1β mediated induction of catabolic
molecules MMP-3, ADAMTS5, syndecan-4 and prolyl
hydroxylase 3 (PHD3), and this inhibition was through
αvβ3 and α5β1 integrins, indicating a protective role of
CCN2 in pathogenesis of disc disease.
Many of the effects of TNF-α and IL-1β on the ECM
are mediated through the NF-κB signalling pathway and
the heparan-sulphate proteoglycan syndecan-4. Fujita et
al. (2012) showed that prolyl hydroxylase 3 (PHD3) acts
as a coactivator of p65 to propagate matrix catabolism
induced by TNF-α. TNF-α treatment of NP cells induces
expression of PHD3, which then interacts with p65 to
promote transcription of syndecan-4, ADAMTS5, MMP13 and COX2. More recent work has confirmed that PHD2
plays a similar role in the NP in promoting p65-mediated
transcription (Li et al., 2015). Syndecan-4 is required
for TNF-α and IL-1β-dependent increase in expression
and activity of ADAMTS5 and MMP-3 in rat NP cells
(Wang et al., 2011; Wang et al., 2014a). Adding another
dimension to cytokine action on disc cells, Ye et al. (2011)
demonstrated a positive relationship between TNF-α and
Wnt/β-catenin signalling in NP cells and showed that
TNF-α activates the Wnt/β-catenin pathway, thereby
increasing expression of MMP-13. Additionally, Wnt
signalling induces TNF-α expression in NP cells, possibly
leading to a pro-degenerative feed-forward loop between
the two signalling pathways (Hiyama et al., 2013).
In vivo studies support the role of these endogenous
cytokines in the degenerative process of the IVD. Mice
lacking functional IL-1ra, an endogenous antagonist for
IL-1R1, demonstrated loss of proteoglycans and increased
expression of MMP-3, -7 and ADAMTS4 in their IVDs.
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Fig. 2. Schematic showing the major phases of intervertebral disc degeneration and discogenic back pain. Potential
triggering events include overt trauma to the disc, altered loading, genetic predisposition and spinal infection. These
triggers result in NP and AF cell-mediated synthesis of cytokines such as TNF-α, IL-1β, and IL-6. These cytokines
have at least three major effects: increased matrix breakdown through production of SDC4, ADAMTS4/5 and MMPs,
activation and chemotaxis of immune cells to the disc, and induction of neurotrophins (NGF, BDNF) by disc cells
and immunocytes. NGF and BDNF induce production of pain-associated channels ASIC3 and Trpv1 in the DRG.
Presence of these factors in the inflammatory microenvironment of the degenerated disc is thought to promote DRG
sensitisation and pain. Blocking of cytokine production in Phases 1 and 2 may have the most profound positive
effect on disease progression and back pain. Red blocking symbols indicate possible areas for clinical intervention.
Abbreviations: ADAMTS4/5, a disintegrin and metalloproteinase with thrombospondin motifs 4/5; ASIC3, acid-sensing
ion channel 3; BDNF, brain-derived neurotrophic factor; β-NGF, β-nerve growth factor; DRG, dorsal root ganglion;
IFN-γ, interferon-γ; MMPs, matrix metalloproteinases; SDC4, syndecan-4; TrpV1, transient receptor potential cation
channel subfamily V member 1. (Adapted from Risbud and Shapiro, 2014)

Compared to wild type mice, discs of IL-1ra-/- mice had
higher histological grade of degeneration, and disc cells
exhibited diminished proliferative capacity (Phillips et al.,
2013). Similarly, Kang et al. (2015) showed that injection
of TNF-α in a porcine model was sufficient to induce
early-stage disc degeneration, characterised by matrix loss,
annular fissure formation, and vascularisation.
Activation of TLRs by endogenous matrix ligands
may exacerbate the disease progression through
cytokine production
Additionally, matrix catabolism products may contribute
to progression of disc disease by serving as endogenous
ligands of TLRs and, thus, exacerbating the inflammatory
state. Biglycan is a small, leucine-rich proteoglycan
expressed in the IVD. Proteolytically-cleaved biglycan has
been shown to activate proinflammatory cascades through
binding to TLR2 and TLR4 in macrophages (Schaefer
et al., 2005). Relevant to this discussion, biglycan has

been shown to be extensively fragmented in pathological
human IVDs (Brown et al., 2012). Similarly, fibronectin
fragments (Fn-f) can act as endogenous ligands for TLR4
(Okamura et al., 2001), fibronectin fragmentation increases
in degenerated discs possibly due to increased ADAM8mediated cleavage (Ruel et al., 2014), and injection
of 30 kDa N-terminal Fn-f in rabbit discs promotes
degeneration (Anderson et al., 2005). Similarly, versican, a
large aggregating proteoglycan that is expressed in the disc
(Sivan et al., 2014), is shown to activate TLR2 and TLR6
(Kim et al., 2009). While the in vivo evidence is limited,
there are indeed studies showing activation of TLR by
ECM components in NP, giving credence to the hypothesis.
Fragments of hyaluronic acid (HA) increase expression
of IL-1β, IL-6, IL-8, MMP-1, and MMP-13 by NP cells
by binding to TLR2 (Quero et al., 2013). Additionally,
excessive mechanical loading of IVD cells, a contributor to
disc disease, has also been shown to upregulate TLR2 and
TLR4 expression (Gawri et al., 2014). Thus, ECM proteins,
particularly fragments generated during the degenerative
process, binding to TLRs on NP cells can potentiate the
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pathogenesis of disc degeneration (See schematic in Fig. 2
for various phases of disc degeneration and possible areas
for intervention, as indicated by red blocking symbols).
Immune cells are activated by disc cells in response
to TNF and IL-1
In addition to affecting matrix homeostasis, cytokines
also induce NP cells to synthesise many cytokines and
chemokines that can further enhance the inflammatory state
by recruiting and activating immune cells. Gruber et al.
(2013) showed that production of IL-17 is correlated with
severity of degeneration and was induced by TNF-α and
IL-1β. Human IVD cells, in response to IL-1β treatment,
increase production of COX-2 and IL-6 as well as IL-1β
itself, creating a positive feedback loop (Jimbo et al., 2005).
When exposed to TNF-α, human IVD cells increased
production of the tachykinin peptide Substance P, which
subsequently induced expression of IL-1β, IL-6 and IL-8,
a chemoattractant for neutrophils (Kepler et al., 2012).
Similarly, IVD cells, following treatment with TNF-α
and IL-1β, produce CCL5/RANTES, a chemoattractant
for macrophages and eosinophils, and the expression
is correlated with both discogenic pain and severity of
degeneration (Kepler et al., 2013; Gruber et al., 2014a).
When treated with IL-1β or TNF-α, both NP and AF cells
produced monocyte chemoattractant protein-1 (MCP-1/
CCL2) in a dose- and time-dependent manner. This was
also demonstrated in a surgically-induced rabbit IVD
herniation model (Yoshida et al., 2002; Yoshida et al.,
2005). Human AF cells also induced expression of MCP-1/
CCL2 in response to IL-1β treatment (Gruber et al., 2015).
Other macrophage chemoattractants, such as CCL3/MIP1α and CCL4/MIP-1β, are expressed by NP cells, and their
expression is regulated by TNF-α or IL-1β through MAPK
and NF-κB pathways. Interestingly, while p65 induces the
expression of CCL3, p50 showed inhibitory effects on
CCL3 expression. Importantly, expression of CCL3 has
been correlated to severity of degeneration in human NP
tissue (Wang et al., 2013b).
It is worth noting that IVD cells themselves express
chemokine receptors, although their physiologic function
and precise role in degeneration is not yet fully elucidated.
IVD cells express CCL5 receptors CCR1, CCR3 and
CCR5 (Gruber et al., 2014a). In a recent report, Phillips
et al. (2015) showed expression of CCR1, CXCR1 and
CXCR2 by human NP cells in situ; expression of CXCR2
significantly correlated with the grade of degeneration.
Surprisingly, NP cells were also positive for CD4, a
receptor exclusively expressed by immune cells, more
prominently by the CD4+ T helper cells, an observation
that requires further careful investigation. Even though
human NP cells expressed these chemokine receptors,
treatment of primary human NP cells with IL-16, CCL2,
CCL3, CCL7 or CXCL8 did not induce inflammatory
responses or ECM remodelling. Rather, IL-1β treatment
was able to induce cytokines and chemokines as well as
ECM remodelling, suggesting IL-1β as a key player in
modulating inflammatory process in intervertebral disc
(Phillips et al., 2015).

Role of cytokines in disc health and disease
TNF and IL-1 affect homeostatic activities of IVD
cells
In addition to the effects on the matrix, inflammatory
cytokines can also directly affect disc cell survival and
functionality. A study from Purmessur et al. (2013) showed
in a bovine organ culture model that TNF-α induced cell
senescence along with anti-anabolic and pro-catabolic
activities of the resident cells. In a rat organ culture model
of disc degeneration, tissues were cultured with TNF-α, IL1β and serum limiting conditions, and showed differential
expression of many genes involved in cell cycle, cell
death, cellular growth and proliferation (Ponnappan et
al., 2011). In addition, human AF cells exposed to both
IL-1β and TNF-α significantly downregulated growth
differentiation factor 5 (GDF5) (Gruber et al., 2014b),
which has previously been demonstrated to be an important
anabolic factor in disc (Li et al., 2004). Microarray analysis
of human outer and inner AF tissue revealed higher GDF5
expression in herniated lumbar discs, compared to nonherniated lumbar discs (Gruber et al., 2014b). Another
central mediator critical to disc cell proliferation is the
Notch signalling pathway (Hiyama et al., 2011). TNF-α
and IL-1β treatment of NP cells increased expression of
NOTCH1 and NOTCH2 receptors along with their ligand
Jagged-2, and downstream transcription factors HES1,
HEY1 and HEY2. In addition, levels of NOTCH2 were
increased in degenerative human NP tissues compared to
non-degenerative samples, suggesting cytokine-mediated
aberration in Notch signalling may affect cellular
proliferation and differentiation in disc degeneration (Wang
et al., 2013a).
There is emerging evidence that even transient exposure
to cytokines may have lasting effects on the IVD. In
a 2014 study, Maidhof et al. (2014) demonstrated that
inflammatory stimuli have a permanent effect on IVD cell
biophysical properties. After 24 h of treatment with TNF-α,
hydraulic permeability and cell radius of NP cells were
altered for 1 week. These authors also noted a decrease
in the expression of water channel Aquaporin 1, which
has been recently shown to be associated with severity of
degenerative disc disease (Maidhof et al., 2014; Johnson et
al., 2015). Similarly, in a bovine disc organ culture model,
short-term TNF-α treatment has been shown to result in
long-term catabolic effects without negatively affecting
cell viability (Purmessur et al., 2013). Likewise, human
AF cells treated with IL-1β displayed greater and sustained
increase in intracellular calcium concentration in response
to laminar fluid flow, indicating IL-1β “sensitises” the AF
to mechanical loading and sheer stress (Elfervig et al.,
2001).
TNF and IL-1 may play a critical role in resolution of
disc herniation
While the high cytokines levels associated with chronic
inflammation negatively affect the ECM and cell viability
during disc degeneration, it is also important to note that
TNF-α and IL-1β (Genevay et al., 2009) play an important
role in natural resolution of disc herniation. It is well known
that the majority of patients with disc herniation do not
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develop symptoms of chronic LBP and radiculopathy due
to neutrophil and macrophage-mediated timely resorption
of the extruded NP tissue (Iwabuchi et al., 2008). One study
has shown that TNF-α was required to induce MMP-3 in
the herniated tissue, which acted as a chemoattractant for
macrophages necessary for resorption (Haro et al., 2000).
Immunoreactivity to TNF-α in the dorsal root ganglion
(DRG) was increased following exposure to NP material
in a rat model of disc herniation (Murata et al., 2004).
Application of TNF-α inhibitor during surgery abrogated
macrophage infiltration and VCAM-1 expression in the
DRG. These results suggest that TNF-α plays a critical role
in the coordination of macrophage infiltration following
herniation of NP tissue (You et al., 2013). Likewise,
inhibition of IL-1 by IL-1ra resulted in decreased active
MMP-3 in human disc herniation samples, suggesting a
contribution of IL-1 to this process (Genevay et al., 2009).
While these results demonstrate the importance
of TNF-α and IL-1 in resolution of disc herniation, as
discussed above, an unchecked inflammatory response is
likely deleterious to the disc. It is therefore desirable to
devise a strategy to carefully control timing and magnitude
of the inflammatory response by using agents such as
sTNFRII (Sinclair et al., 2011), IL-1ra (Le Maitre et al.,
2006; Shamji et al., 2007; Gorth et al., 2012), and antichemotactic agents (Wang et al., 2013b).
New therapies and future directions for the treatment
of disc disease
Several approaches have been studied to counteract the
effects of TNF-α on disc degeneration. BMP-7 is able
to counteract TNF-α-induced activation of NF-κB and
subsequent induction of ADAMTS4 and ADAMTS5,
thereby preventing TNF-induced matrix loss in human
disc cells (Wang et al., 2014b). Platelet rich plasma, or
PRP, has also been shown to reduce the TNF- and IL-1mediated decreases in collagen II and aggrecan expression
levels in human NP cells (Kim et al., 2014). Finally, LIM
mineralisation protein-1 (LMP-1) has recently been shown
to prevent TNF-α-mediated induction of MMP-3 and -13
in rat NP cells (Liu et al., 2015).
A recent study by Walter et al. (2015b) demonstrated
that production of IL-1β, IL-6 and IL-8 by diseased human
NP cells in response to TNF-α was at vastly different rates
and magnitudes, suggesting different roles these cytokines
may play in disc disease. Unlike reported by previous
studies, blocking IL-6 or IL-1β did not affect the expression
of other pro-inflammatory cytokines in response to TNF-α
treatment. Anti-TNF-α therapy, given at the same time
as TNF-α stimulation, was most effective at inhibiting
expression of these cytokines (Walter et al., 2015b).
Other studies have suggested a possible role for antiIL-1β therapy as a treatment modality. Co-treatment of
agarose-encapsulated bovine NP cells with both IL-1β
and IL-1ra abolished the catabolic effect caused by IL1β (Smith et al., 2011). When IL-1ra was introduced
to degenerate human IVD explants, matrix degradation
as well as expression of MMPs and ADAMTSs were
successfully blocked (Le Maitre et al., 2007a). Similarly,
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medium conditioned with IL-1ra encapsulated in PLGA
microspheres was effective in attenuating the effect of IL1β on bovine NP cells (Gorth et al., 2012). Shamji et al.
(2007) used recombinant human elastin-like polypeptide
(ELP)-IL-1ra fusion protein to promote prolonged release
of IL-1ra, and were successful in decreasing TNF-α
expression and ADAMTS4 and MMP-3 transcription in
human IVD cells. In addition, Krupkova et al. (2014)
demonstrated that degenerate human IVD cells treated in
vitro with epigallocatechin 3-gallate (EPCG) significantly
inhibited the expression of pro-inflammatory cytokines and
MMPs in response to IL-1β treatment, and also showed in
vivo reduction of radiculopathic pain in rats treated with
EPCG.
A study by Gu et al. (2015) showed miR-146a has a
protective effect on IL-1-induced IVD degeneration. When
bovine NP cells transfected with a miR-146a mimic were
treated with IL-1, induction of inflammatory cytokines
and matrix protease gene expression was decreased.
Additionally, IVDs from miR-146a-/- mice ex vivo showed
greater degradation of proteoglycan and increased
level of MMP-13 and ADAMTS-5 after treatment with
IL-1, suggesting a new potential therapeutic approach
in modulating IL-1 activity in disc disease (Gu et al.,
2015). Importantly, in addition to these laboratory-based
investigations, few clinical studies have tested efficacy of
anti-TNF-α and anti-IL-1β therapies for treatment of back
and radicular pain (see Table 1 for details). These clinical
studies suggest that anti-cytokine therapies as well as, in
a subset of patients, antibiotic regimens hold promise in
treating low back and radicular pain.
Current treatment modalities for disc degeneration
and LBP are limited and lack efficacy (Martin et al.,
2008; Williams et al., 2014). Therefore, these new,
targeted therapeutic strategies hold much promise. Careful
consideration must be taken, however, when using anticytokine treatment. As mentioned above, TNF-α and
IL-1β play necessary positive roles in natural resolution
of NP herniation. Additionally, also mentioned above,
even transient exposure to LPS or TNF-α results in
lasting biophysical changes in NP cells (Maidhof et al.,
2014). In light of this evidence, the timing of targeted
anti-inflammatory treatment modalities is likely to have a
critical impact on overall efficacy and success of therapy.
Although a definitive “cure” for disc degeneration is
far in the future, current research is providing hope for
researchers and clinicians for improving patient outcomes
for degenerative disc disease and LBP.
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Table 1. Clinical trials of different therapeutic modalities for low back and radicular pain.
Drug
Etanercept
(TNF-α decoy
receptor)

Study design
Multicentre, double-blind, RCT for
treating symptomatic lumbar disc
herniation

Outcome
Two transforaminal injections of etanercept resulted in
clinically and statistically significant reduction in worst back
pain and mean daily worst leg pain at 4 weeks post-treatment
(Freeman et al., 2013)
Prospective, randomized trial for
Epidural injection of etanercept was more effective than
treating radicular pain in patients with dexamethasone for improving low back pain, leg pain, and leg
lumbar spinal stenosis
numbness (Ohtori et al., 2012)
Multicentre, 3-group, RCT for
No improvement when compared to placebo, and had worse
treating pain due to lumbosacral
efficacy than epidural steroid injection in improving pain and
radiculopathy
functionality (Cohen et al., 2012)
Triple-blind RCT for treating acute
The ODI and VAS improved at 6 weeks and at a 3-month
sciatica secondary to lumbar disc
follow-up (Okoro et al., 2010)
herniation
Double-blind, controlled study
Significant improvements in leg and back pain at 6 months
for treating patients with subacute
(Cohen et al., 2009)
lumbosacral radiculopathy
Open cohort, historical group
Improvement of leg pain, low back pain at 6 weeks, as well as
controlled study for treating patients Roland Morris disability questionnaire and the ODI (Genevay
with severe sciatica
et al., 2004)
Adalimumab
Multicentre, double-blind, RCT for
Small but significant improvement in sciatica, and fewer
(Anti-TNF-α antibody) treating acute and severe sciatica
surgical procedures in short term, and markedly reduced back
and imaging-confirmed lumbar disc
surgery in a 3-year follow-up (Genevay et al., 2010; Genevay
herniation
et al., 2012)
Infliximab
RCT for treating patients with acute/ No difference compared to placebo group in improving pain
(Anti-TNF-α antibody) subacute sciatica due to herniated disc at 1 year, but shortened symptom duration and less straight
leg raising restriction in cases of L4-L5/L3-L4 herniation with
Modic change (Korhonen et al., 2006)
IL-1Ra-enriched
Prospective, double-blind, reference- Significant clinical improvements and VAS score, and
Authologous
controlled, single centre, investigator- reduction in pain and disability, ACS showed statistically
Conditioned Serum
initiated study for treatment of lumbar significant superiority over triamcinolone at week 22 (Becker
(ACS; Orthokine)
back pain
et al., 2007)
Bioclavid
Double-blind, RCT for treatment of
Statistically significant improvement on lumbar pain, leg pain,
(Amoxicillinchronic low back pain and Modic type and disease-specific disability in antibiotic-treated group at 1
clavulanate)
1 changes
year (Albert et al., 2013)
Pilot prospective uncontrolled study
Clinically and statistically significant improvement in low
for treating patients with low back
back pain intensity, number of days with pain, disease-specific
pain and Modic type 1 changes
and patient-specific function, and global perceived effect at
long-term follow up (mean 10.8 months) (Albert et al., 2008)

Abbreviations: RCT, randomised controlled trial; VAS, visual analogue scale; ODI, Oswestry disability index.
and there has been no significant financial support for this
work that could have influenced its outcome.
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Discussion with Reviewers
Reviewer I: In the concluding paragraph the importance
of the appropriate timing of anti-inflammatory treatment
is highlighted. In view of the phases described in Fig. 2, at
which stage(s) would anti-inflammatory therapy be most
appropriate?
Authors: Because of the chronic and progressive nature
of disc disease, anti-inflammatory treatments are best
started earlier in the disease process. We are therefore of
the opinion that Phases I and II would be most appropriate
for anti-inflammatory therapy. The caveat, however, is
that often times the disease is not clinically manifested
until much later in its course, which likely would limit the
maximal benefits of such treatments.
Reviewer II: The study by Albert et al. (2013b) has raised
major interest amongst clinicians. How much relevance do
the authors assign to bacterial infection during degenerative
disc disease and which approach would they apply to
further investigate this aspect?
Authors: The nucleus pulposus is an avascular and
confined tissue, making bacterial colonisation difficult
when the continuity of the tissue is maintained, thus
making primary infection of the nucleus pulposus an
unlikely initiating cause of disc disease. The Albert study
does suggest, however, that bacterial infection in a certain
subset of patients can at least promote symptomatic disc
disease and chronic LBP. It is important to note that all
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of the patients in the Albert study had previous nuclear
herniations, where extruded NP material would be exposed
to vasculature and surrounding connective tissue, and
Type I Modic changes. It would therefore be interesting
to explore whether a correlation exists between persistent
and refractory LBP following herniation, and increased
likelihood of bacteraemia (e.g. prolonged catheter use,
recent oral surgery, history of infective endocarditis,
etc.), when disc material could potentially be colonised.
One could then investigate whether bacterial infection
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post-herniation alters hernia resolution and/or promotes
persistent inflammatory and nociceptive cascades with
involvement of immune cells. A more comprehensive
study that does not exclude chronic LBP patients without
Modic changes would further provide understanding of the
potential contribution of bacterial infection to progression
of disc disease in the general population.
Editor’s Note: Scientific Editor in charge of the paper:
Stephen Ferguson.
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